Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Plans To Audit Its New 510(k) Refuse-To-Accept Program

This article was originally published in The Gray Sheet

Executive Summary

Results of the planned June audit will be of significant interest to a number of device companies that claim FDA reviewers have erroneously crossed into substantive review territory in applying the new "quick review" procedure.

You may also be interested in...



More Leeway For Reviewers In Updated 510(k) 'Refuse-To-Accept' Policy

An updated 510(k) “refuse to accept” guidance document gives FDA staff more opportunity to work with sponsors to smooth out product submissions without repeatedly halting and restarting the review clock with RTA determinations.

Industry, FDA Start To Settle Into 510(k) Refuse-To-Accept Program

After a rocky start, the rate of 510(k)s being turned away by FDA before full review under the refuse-to-accept program has steadily declined, and industry expects continued improvement.

Small Uptick In 510(k) Clearances In Fiscal 2014

FDA cleared 3,103 510(k)s in the fiscal year that ended Sept. 30, averaging about 259 per month, based on a review a FDA’s monthly 510(k) listings. That is up from 2,995 clearances – a 250 per-month average – in FY 2013.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel